Form D · Pharmaceuticals

Primmune Therapeutics, Inc.

San Diego, CA · CIK 0001721931

Offering snapshot reported Nov 6, 2020 · SEC filing

Reported sold
$13M
Offering amount: $24M
Investors reported
12
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 23, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 6, 2020Initial$13,000,009No comparison12SEC filing
Mar 17, 2020Initial$2,500,000No comparison2SEC filing
Mar 17, 2020Initial$1,100,000No comparison19SEC filing
Mar 17, 2020Initial$2,000,000No comparison17SEC filing
Jan 30, 2018Amendment$1,525,000$855,000vs Nov 8, 201736SEC filing
Nov 8, 2017Initial$670,000No comparison17SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-379891

Source: Form D, filed Nov 6, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
James R. Appleman Director, Executive
Todd J. Harris Director
Charles Mc Dermott Director, Executive
Scott Morenstein Director
Amir Nashat Director
Paulo S. Rangel Executive
Andrew Rubinstein Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
C/O Jlabs San Diego 3210 Merryfield Row
San Diego, CA, 92121